Upamostat clinical trials
Also written WX-671.
How each study uses upamostat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Henry M. Jackson Foundation for the Advancement of Military Medicine (1) · Heidelberg Pharma AG (1) · RedHill Biopharma Limited (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses upamostat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19CompletedPhase 2Henry M. Jackson Foundation for the Advancement of Military MedicineNCT05954286Written as Upamostat
- Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseTerminatedPhase 2/3RedHill Biopharma LimitedNCT04723537Written as Part A: Upamostat 200 mg
- Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast CancerCompletedPhase 2Heidelberg Pharma AGNCT00615940Written as WX-671
Codes
What other systems call upamostat · ClinicalTrials.gg INT006264
- MeSH (NLM) C580590upamostatOne source NLM
- UNII (FDA) S5M7KW6U17UPAMOSTATConfirmed FDA, NLM
- NCI Thesaurus C73985UpamostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C580590 | upamostat | One source NLM |
| UNII (FDA) | S5M7KW6U17 | UPAMOSTAT | Confirmed FDA, NLM |
| NCI Thesaurus | C73985 | Upamostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.